BEIJING, Oct. 22, 2025 — The “Healthy China: AI + Weight Management” Innovation Symposium took place at the National People’s Congress Conference Center. This event, organized with guidance from the China Food and Drug Institutions Quality and Safety Promotion Association (FDSA), was co-hosted by Fangzhou Inc. (06086.HK), referred to as “Fangzhou” or “the Company,” a prominent provider of AI-powered internet healthcare solutions.
Mao Zhenbin, President of the FDSA, commenced the symposium with opening remarks. The gathering attracted a distinguished group of experts, including top academics, medical practitioners, and industry figures. Among those present were Professor Chen Runsheng, a scientist and doctoral supervisor from the Chinese Academy of Sciences’ Institute of Biophysics; Professor Ren Fazheng, a professor and doctoral supervisor at the China Agricultural University’s College of Food Science and Nutritional Engineering; Professor Yu Xiaodong, who previously served as Deputy Director of the China Academy of Macroeconomic Research’s Economic Research Institute, and currently chairs the China Health Industry Alliance and directs the National Public Nutrition Improvement Project Steering Committee; and Qian Lei, Chief R&D Officer (General Biomedicine) for Innovent Biologics.
The symposium’s agenda was carefully aligned with China’s key national health objectives. Participants engaged in comprehensive discussions regarding AI’s potential to advance the next stage of China’s public health strategy. Fangzhou, recognized as China’s foremost AI-powered chronic disease management platform, unveiled its comprehensive “AI + Weight Management” solution. Dr. Xie Fangmin, Fangzhou’s Founder, Chairman, and CEO, delivered a keynote address, detailing how AI technologies can enhance the accuracy, safety, and sustained effectiveness of weight loss programs.
Since 2024, China has prioritized weight management as a national health focus, incorporating it into the Healthy China 2030 strategy through various government-backed programs. Dr. Xie commented, “Our aim is to vigorously support this vital national health goal by using AI to provide the public with expert, evidence-based personal weight management solutions — thereby tackling the underlying causes of numerous chronic disease risks.”
Utilizing its exclusive “XingShi” Large Language Model (XS LLM), Fangzhou’s platform incorporates AI-driven tools like its AI Doctor Assistant, AI Health Manager, and AI Medication Finder to offer a comprehensive, closed-loop weight management system. Users have the option to submit their BMI data or health records to obtain personalized advice, and those needing medication can receive around-the-clock AI-powered guidance and continuous support from certified medical practitioners.
The symposium occurred amidst China’s escalating “Healthy Weight Management” initiative, a core component of the Healthy China 2030 strategy. Experts present at the event highlighted that AI technologies are revolutionizing the international weight-loss sector, with China’s market alone anticipated to exceed RMB 50 billion by 2030.
Earlier in the year, Fangzhou unveiled strategic alliances with Novo Nordisk and Innovent Biologics to develop AI-driven weight management solutions, marking a substantial step forward in digital healthcare partnerships. During the symposium, Fangzhou was designated as a founding core enterprise for the national “Healthy China: AI + Weight Management Pioneer” initiative, a joint endeavor aimed at establishing industry benchmarks, promoting innovation, and informing the public about scientifically supported weight management.
Moving forward, Fangzhou intends to broaden its “AI + Weight Management” ecosystem through expanded applications, innovation guided by data, and partnerships across various industries. By developing an intelligent, standardized, and cooperative framework, the Company seeks to reshape China’s weight management sector and support the nation’s enduring health objectives.
About Fangzhou Inc.
Fangzhou Inc. (06086.HK) operates as China’s premier online platform for chronic disease management, catering to 52.8 million registered users and 229,000 physicians as of June 30, 2025. The Company focuses on providing customized medical care and AI-enhanced precision medicine solutions. For further details, please visit .
Media Contact
For additional questions or interview requests, kindly contact:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com
Disclaimer: This press release includes forward-looking statements. Actual outcomes could significantly vary from projections due to a range of factors. Readers are advised against placing excessive trust in these statements.
